Depemedrone (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00523692 (ClinicalTrials.gov) | September 2007 | 30/8/2007 | Remission Induction in Very Early Rheumatoid Arthritis | Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy | Rheumatoid Arthritis | Drug: Etanercept, methotrexate and depomedrone;Drug: depemedrone | University Hospital Birmingham | Wyeth is now a wholly owned subsidiary of Pfizer | Not yet recruiting | 18 Years | N/A | Both | 20 | Phase 4 | United Kingdom |